Genedx Holdings CORP Schedule 13G passive stakes

The Goldman Sachs Group, Inc. and its subsidiary Goldman Sachs & Co. LLC have filed a Schedule 13G, reporting beneficial ownership of 5.8% of GenEdx Holdings Corp.'s Class A common stock as of June 30, 2026.

ARK Investment Management LLC, led by Catherine D. Wood, has reported beneficial ownership of 5.33% of GeneDx Holdings Corp.'s common stock, signaling a notable investment position.

BlackRock, Inc. has reported a beneficial ownership of 5.5% in GeneDx Holdings Corp. Class A Stock, as of June 30, 2026.

William Blair Investment Management, LLC has reported a 4.3% beneficial ownership stake in GeneDx Holdings Corp. common stock.

Summit Partners and its affiliates have disclosed a 3.04% beneficial ownership stake in GeneDx Holdings Corp. Class A common stock, totaling 867,265 shares.

FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G, disclosing beneficial ownership of 0.6% of GeneDx Holdings Corp.'s Class A Common Stock as of June 30, 2025.

William Blair Investment Management, LLC has reported a 5.7% beneficial ownership stake in GeneDx Holdings Corp., holding 1,631,402 shares of common stock.

FMR LLC and its Chairman and CEO, Abigail P. Johnson, have jointly disclosed a beneficial ownership of 10.0% in GENEDX HOLDINGS CORP's Class A Common Stock as of March 31, 2025.

Goldman Sachs Group and its subsidiary Goldman Sachs & Co. LLC have filed an amended Schedule 13G, disclosing a passive beneficial ownership of 3.9% in GENEDX HOLDINGS CORP.'s Class A common stock, indicating a reduction from a previously held stake above 5%.

Multiple entities and individuals associated with Summit Partners have disclosed beneficial ownership of 5.19% of GeneDx Holdings Corp.'s Class A common stock.

The Goldman Sachs Group, Inc. and its subsidiary Goldman Sachs & Co. LLC have reported a passive beneficial ownership of 5.2% in GENEDX HOLDINGS CORP.'s Class A common stock.